{
  "report_rows": [
    {
      "kpi": "Revenue (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$4.34B vs. cons $4.30B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted Diluted EPS (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$3.08 vs. cons $3.03",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "R&DS book-to-bill (service-fee/TTM)",
      "prediction": "MISS",
      "answer": "pred ~1.08x vs. cons ~1.15x",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 Revenue guide",
      "prediction": "BETTER",
      "answer": "guide ~$17.35B vs. cons $17.30B (FY2026, narrow raise)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY26 Adjusted EBITDA guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4.00B vs. cons $4.00B (FY2026, reaffirm \u2014 the disappointment)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 Adjusted EPS guide",
      "prediction": "BETTER",
      "answer": "guide ~$12.90 vs. cons $12.80 (FY2026, buyback-driven EPS raise)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3'26 Adj EPS guide",
      "prediction": "UNKNOWN",
      "answer": "guide ~$3.20 vs. cons $3.22 (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.5,
  "day5_path": "FADE",
  "day5_rationale": "Stock is up ~35% since early May and ~28% off June lows into the print, sitting near the top of the $225 analyst target range \u2014 priced for a beat-and-raise. Even with a likely revenue/EPS beat, the quality is low: EPS upside is buyback/FX-driven while EBITDA guide is only reaffirmed (not raised) and R&DS book-to-bill likely fails to normalize back to the hoped ~1.15x. Large-pharma decision speed stays 'deliberate,' so out-quarter service-fee revenue conversion gets trimmed and the operational revisions are muted-to-negative even after the headline beat. The out-period math (soft bookings mix + no EBITDA raise) pulls forward estimates down, so the overbought move fades over the week.",
  "day5_confidence": "MEDIUM"
}